Login to Your Account

Amgen, Regeneron benefit from evacetrapib's demise

Acceding to the recommendation of an independent data monitoring committee (DMC), Eli Lilly and Co. said it was terminating the phase III ACCELERATE study of evacetrapib (formerly LY2484595) in high-risk atherosclerotic cardiovascular disease for lack of efficacy, bringing the program to an abrupt end. more »

Our Habitat for All Things Science
Vaccines are bright spot in infectious disease fight

SAN DIEGO – Predictions at the International Conference on Antimicrobials and Chemotherapy and the International Congress of Chemotherapy (ICAAC/ICC) 2015 annual meeting tend to be of the dire sort, warning of a return to the pre-penicillin era. So it was a pleasant exception to listen to Glaxosmithkline plc's Rino Rappuoli brim with optimism during his plenary talk on challenges and opportunities of vaccines.



Partners in Focus